Short answer
Krystal Biotech, Inc. (KRYS) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $116M (up 31.9% year over year) with net income of $56M.
Q1 2026 key financials · XBRL
- Revenue
- $116M
- +31.9% YoY
- Net income
- $56M
- +56.5% YoY
- Operating margin
- 46.1%
- EPS (diluted)
- $1.83
- +52.5% YoY
Source: XBRL data from the Krystal Biotech, Inc. (KRYS) Q1 2026 10-Q on SEC EDGAR. USD.
Krystal Biotech, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk Factors section not provided in submitted text
- No new or changed regulatory, legal, operational, competitive, market, or financial risks identifiable
- Rule 10b5-1 plan adopted by executive for up to 1,903 shares through December 31, 2026
- Director’s prior trading plan terminated after 71,964 shares sold
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Krystal Biotech, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.